title: Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.
abstract: Novel, exciting intervention strategies to prevent infection with HIV have been tested in the past year, and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review, prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners; GSK, Novartis and Sanofi-Pasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries (Tanzania, Mozambique, South Africa, Kenya, Malawi, Rwanda), and is directly supporting clinical trials including MABGEL, a gp140-hsp70 conjugate trial and HIVIS, vaccine trials in Europe and Africa.
authors.affiliation: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Nobels väg, Stockholm, 171 77, Sweden.
authors.forename: Sarah
authors.initials: S
authors.lastname: Brinckmann
authors.forename: Kelly
authors.initials: K
authors.lastname: da Costa
authors.forename: Marit J
authors.initials: MJ
authors.lastname: van Gils
authors.forename: David
authors.initials: D
authors.lastname: Hallengärd
authors.forename: Katja
authors.initials: K
authors.lastname: Klein
authors.forename: Luisa
authors.initials: L
authors.lastname: Madeira
authors.forename: Lara
authors.initials: L
authors.lastname: Mainetti
authors.forename: Paolo
authors.initials: P
authors.lastname: Palma
authors.forename: Katharina
authors.initials: K
authors.lastname: Raue
authors.forename: David
authors.initials: D
authors.lastname: Reinhart
authors.forename: Marc
authors.initials: M
authors.lastname: Reudelsterz
authors.forename: Nicolas
authors.initials: N
authors.lastname: Ruffin
authors.forename: Janna
authors.initials: J
authors.lastname: Seifried
authors.forename: Katrein
authors.initials: K
authors.lastname: Schäfer
authors.forename: Enas
authors.initials: E
authors.lastname: Sheik-Khalil
authors.forename: Annette
authors.initials: A
authors.lastname: Sköld
authors.forename: Hannes
authors.initials: H
authors.lastname: Uchtenhagen
authors.forename: Nicolas
authors.initials: N
authors.lastname: Vabret
authors.forename: Serena
authors.initials: S
authors.lastname: Ziglio
authors.forename: Gabriella
authors.initials: G
authors.lastname: Scarlatti
authors.forename: Robin
authors.initials: R
authors.lastname: Shattock
authors.forename: Britta
authors.initials: B
authors.lastname: Wahren
authors.forename: Frances
authors.initials: F
authors.lastname: Gotch
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D000890:Anti-Infective Agents / Q000276:immunology*; D000917:Antibody Formation / Q000276:immunology; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans
chemical_list: D016915:AIDS Vaccines; D000890:Anti-Infective Agents